Luxembourg-based Creabilis SA, which specialises in treatments in dermatology, inflammation and pain, has appointed Catherine Moukheibir to its board of directors. Ms Moukheibir is currently senior advisor for finance and a member of the executive committee, at Innate Pharma where she was responsible for that company’s licensing deal in 2011 with Bristol-Myers Squibb for an early-stage cancer compound. She has an MA and MBA from Yale University in the US.
Creabilis announced the appointment on 28 February 2013.
Copyright 2013 Evernow Publishing Ltd.